Compare INSG & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | COYA |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 124.8M |
| IPO Year | 2000 | 2022 |
| Metric | INSG | COYA |
|---|---|---|
| Price | $6.64 | $4.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $15.33 | ★ $15.80 |
| AVG Volume (30 Days) | 241.9K | ★ 266.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $313,832,000.00 | $7,945,753.00 |
| Revenue This Year | $16.21 | N/A |
| Revenue Next Year | $13.28 | $763.10 |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $6.28 | $3.71 |
| 52 Week High | $21.90 | $7.75 |
| Indicator | INSG | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 23.12 | 33.98 |
| Support Level | N/A | $3.90 |
| Resistance Level | $12.95 | $5.18 |
| Average True Range (ATR) | 0.45 | 0.34 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 0.45 | 2.99 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.